Diabetes News

Use of glucagon-like peptide-1 receptor agonists was associated with a reduced risk for progression to cirrhosis and other complications in patients with metabolic dysfunction-associated steatotic liver disease and diabetes, data showed.

Adults with type 2 diabetes using metformin before or during a SARS-CoV-2 infection may have a lower risk for long COVID than those using other diabetes medications, according to findings published in Diabetes Care.

In patients with basal insulin-treated type 2 diabetes, sotagliflozin was associated with greater time in range compared with placebo at 18 weeks, researchers reported at the European Association for the Study of Diabetes Annual Meeting.

Use of AI in medicine is growing quickly. Clinicians are eager to learn what the technology can do, and speakers at meetings across specialties are envisioning its effects — good and bad — in practice management and patient care.

In a first-in-human study, a novel oral amylin and GLP-1 receptor coagonist was safe and tolerable and lowered weight compared with placebo at 12 weeks in patients with obesity, researchers reported.

The FDA has cleared a continuous glucose monitoring system with an implantable sensor that can be worn for up to 1 year for adults aged 18 years and older with type 1 or type 2 diabetes, according to a press release.

Adults who drink caffeinated beverages such as coffee or tea may have a lower risk for developing multiple cardiometabolic diseases compared with adults with low or no intake, according to study findings.

In patients with obesity and heart disease, semaglutide 2.4 mg reduced risk for major adverse cardiovascular events regardless of baseline kidney function, according to new data from the SELECT trial.

A once-weekly GLP-1/glucagon dual agonist conferred greater decreases in HbA1c and body weight than the GLP-1 receptor agonist dulaglutide for adults with type 2 diabetes, according to a presenter.